AbCellera Biologics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.05.23	AbCellera Reports Q1 2023 Business Results (Businesswire)
03.05.23	Ausblick: AbCellera Biologics informiert über die jüngsten Quartalsergebnisse (finanzen.net)
19.04.23	Erste Schätzungen: AbCellera Biologics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
17.04.23	AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023 (Businesswire)
11.04.23	AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 (Businesswire)
06.04.23	AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023 (Businesswire)
22.03.23	AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease (Businesswire)
14.03.23	AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023 (Businesswire)
23.02.23	AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023 (Businesswire)
21.02.23	AbCellera Reports Full Year 2022 Business Results (Businesswire)
20.02.23	Ausblick: AbCellera Biologics gewährt Anlegern Blick in die Bücher (finanzen.net)
06.02.23	Erste Schätzungen: AbCellera Biologics stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
01.02.23	AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 (Businesswire)
24.01.23	AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 (Businesswire)
20.01.23	AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent (Businesswire)
04.01.23	AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 (Businesswire)
15.12.22	AbCellera Up 5% Following Deal With AbbVie (RTTNews)
15.12.22	AbCellera and AbbVie Partner to Advance New Antibody Therapies (Businesswire)
01.12.22	AbCellera, Rallybio To Develop, And Commercialize Antibody-Based Therapeutics For Rare Diseases (RTTNews)
01.12.22	AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases (Businesswire)
01.12.22	FDA Pulls Emergency Use Authorization For Lilly's COVID-19 Antibody Drug (RTTNews)
10.11.22	AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 (Businesswire)
08.11.22	AbCellera Reports Q3 2022 Business Results (Businesswire)
07.11.22	Ausblick: AbCellera Biologics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
04.11.22	AbCellera to Present at Upcoming Investor Conferences in November (Businesswire)
02.11.22	AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development (Businesswire)
24.10.22	Erste Schätzungen: AbCellera Biologics präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
11.10.22	AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022 (Businesswire)
05.10.22	AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022 (Businesswire)
21.09.22	AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic (Businesswire)
09.08.22	AbCellera Reports Q2 2022 Business Results (Businesswire)
08.08.22	Ausblick: AbCellera Biologics gewährt Anlegern Blick in die Bücher (finanzen.net)
03.08.22	AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients (Businesswire)
27.07.22	Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies (Businesswire)
25.07.22	Erste Schätzungen: AbCellera Biologics gewährt Anlegern Blick in die Bücher (finanzen.net)
12.07.22	AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022 (Businesswire)
29.06.22	Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options (Businesswire)
10.05.22	AbCellera Reports Q1 2022 Business Results (Businesswire)
09.05.22	Ausblick: AbCellera Biologics präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
03.05.22	AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration (Businesswire)
26.04.22	AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022 (Businesswire)
25.04.22	Erste Schätzungen: AbCellera Biologics veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
12.04.22	AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 (Businesswire)
08.04.22	AbCellera Presents Data on T Cell Engager Platform at AACR 2022 (Businesswire)
24.02.22	AbCellera Reports Full Year 2021 Business Results (Businesswire)
23.02.22	AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools (Businesswire)
23.02.22	Ausblick: AbCellera Biologics gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
11.02.22	AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 (Businesswire)
11.02.22	AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 (Businesswire)
11.02.22	Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu AbCellera Biologics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten